Sartorius Stedim Biotech GmbH, Goettingen, and Bayer Technology Services GmbH (BTS), Leverkusen, have signed a cooperation agreement on the manufacture and worldwide marketing of BTS` UVivatec® technology
developed to inactivate viruses in biopharmaceuticals by UVC irradiation. Typically used for virus inactivation of cell culture media, antibody solutions and irradiation of vaccines and therapeutics produced from blood and plasma,further areas of application, such as
removal of mycoplasma from bioreactor media, are currently being assessed.
Regulations concerning viral safety in biopharmaceutical manufacturing processes already require manufacturers to provide at least two complementary technologies for virus clearance, during early clinical phases.
This partnership now adds a third method to Sartorius Stedim Biotech`s portfolio, creating what has been described as an “orthogonal technology platform†for broad spectrum virus removal through
nanofiltration, adsorption and now UVC irradiation products.
The technology is scalable and will be marketed as single-use modules, laboratory bench units and process systems with joint collaboration on further process development and engineering services, as well as
advancement of the technology.
Following the partnership agreement, Sartorius Stedim Biotech has signed a purchase contract with the Belgian Red Cross on patents to use UVC technology for blood fractionation and manufacture of biotech
products.
Product directory
.jpg)
2.jpg)
